Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 5, 2005, Pages 495-500

  Koukourakis, Michael I ^a   Manavis, John ^a   Simopoulos, Costantinos ^a   Liberis, Vasilis ^a   Giatromanolaki, Alexandra ^a   Sivridis, Efthimios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Breast cancer; c erbB 2; Docetaxel; Liposomal doxorubicin; Radiotherapy; Trastuzumab

Indexed keywords

AMIFOSTINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB; TROPISETRON;

ADULT; AGED; ARTICLE; BACKACHE; BLOOD TOXICITY; BREAST CANCER; CANCER RELAPSE; CELL PROTECTION; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; MUCOSA INFLAMMATION; ONCOGENE C ERB; ONYCHOLYSIS; RADIOSENSITIZATION; SKIN TOXICITY; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOXORUBICIN; DRUG CARRIERS; FEASIBILITY STUDIES; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; RECEPTOR, ERBB-2; TAXOIDS;

EID: 26444519780     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000182440.11653.5f     Document Type: Article

References (43)

1. Yarden Y. The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37:3-8.
2. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol. 2002;29:231-245.
3. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998;16:1340-1349.
4. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702-2708.
5. Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat. 2000;59:171-175.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
7. Formenti SC, Spicer D, Skinner K, et al. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:397-405.
8. Koukourakis MI, Giatromanolaki A, Galazios G, et al. Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference? Br J Cancer. 2003;88:711-717.
9. Shenkier T, Weir L, Levine M, et al. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ. 2004;170:983-994.
10. Giannakakis D, Koukourakis M, Sotiropoulou A, et al. Accelerated hyperfractionation of radiotherapy for rapidly growing inoperable breast cancer unresponsive to chemotherapy. Tumori. 1992;78:326-329.
11. Svoboda VH, Krawczyk J, Kiawczyk A. Seventeen years experience with accelerated radiotherapy for carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1992;24:65-71.
12. Kosma L, Koukourakis M, Skarlatos J, et al. Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally "far advanced" breast cancer. Am J Clin Oncol. 1997;20:562-566.
13. Koukourakis MI, Yannakakis D. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae. Anticancer Res. 2001;21:2973-2978.
14. Denham JW, Hamilton CS, Christie D, et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer-toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Institution study. Int J Radiat Oncol Biol Phys. 1995;31:305-313.
15. Koukourakis MI, Giatromanolaki A, Kouroussis C, et al. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. Int J Radiat Oncol Biol Phys. 2002;52:144-155.
16. Morgan DA, Berridge J, Blarney RW. Postoperative radiotherapy following mastectomy for high-risk breast cancer. A randomised trial. Eur J Cancer. 2002;38:1107-1110.
17. Nabholtz JM, Reese DM, Lindsay MA, et al. Docetaxel in the treatment of breast cancer: an update on recent studies. Semin Oncol. 2002;29:28-34.
18. Rivera E. Current status of liposomal anthracycline therapy in metastatic breast cancer. Clin Breast Cancer. 2003;4:76-83.
19. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999;9:12-26.
20. Koukourakis MI, Bahlitzanakis N, Froudarakis M, et al. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer. 1999;80:1792-1796.
21. Viret F, Ychou M, Goncalves A, et al. Docetaxel and radiotherapy and pancreatic cancer. Pancreas. 2003;27:214-219.
22. Fujii M, Tsukuda M, Satake B, et al. Japan Cooperative Head and Neck Oncology Group (JCHNOG). Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol. 2004;9:107-112.
23. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol. 1999;17:3512-3521.
24. Koukourakis MI, Koukouraki S, Fezoulidis I, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer. 2000;83:1281-1286.
25. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy. Acta Oncol. 2000;39:207-211.
26. Zhou H, Kim YS, Peletier A, et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys. 2004;58:344-352.
27. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys. 2000;48:1519-1528.
28. Macejewski B, Taylor JM, Wither HR. Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol. 1986;7:323-326.
29. Koukourakis MI, Damilakis J. LQ-based model for biological radiotherapy planning. Med Dosim. 1994;19:269-277.
30. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. Semin Oncol. 2002;29:2-8.
31. Shaw LM, Bonner HS, Schuchter L, et al. Pharmacokinetics of amifostine: effects of dose and method of administration. Sem Oncol. 1999;26:34-36.
32. World Health Organization: Handbook for reporting results of cancer treatment. Geneva, WHO Offset Publ. 1979.
33. RTOG late effects working group. LENT SOMA tables. Radiother Oncol. 1995;35:17-60.
34. Nyati MK, Maheshwari D, Hanasoge S, et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res. 2004;10:691-700
35. Liang K, Lu Y, Jin W, et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003;2:1113-1120.
36. Koukourakis MI, Simopoulos C, Polychronidis A, et al. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? Anticancer Res. 2003;23:1673-1680.
37. Sartor CI. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol. 2003;13:22-30.
38. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha(HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995-4004.
39. Semenza GL. HF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001;13:167-171.
40. Giatromanolaki A, Koukourakis MI, Simopoulos C, et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res. 2004;10:7972-7977.
41. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53:1192-1202.
42. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61:2911-2916.
43. Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell. 2004;5:405-406.